Navigation Links
Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain
Date:9/8/2011

SAN FRANCISCO, Sept. 8, 2011 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that dosing began in a Phase 1 clinical study to evaluate multiple ascending doses of NKTR-181, the company's novel opioid analgesic drug candidate. NKTR-181 is in development as a once- or twice-daily oral tablet for the treatment of chronic pain, and is designed to address the abuse liability and serious central nervous system (CNS) side effects associated with current opioid therapies. Chronic pain conditions, such as osteoarthritis, back pain and cancer pain, affect at least 126 million adults in the U.S. annually and contribute to over $100 billion a year in lost productivity(1).

The multiple ascending dose study is the second study in the Phase 1 clinical program for NKTR-181.  The first study, a single ascending dose trial in 110 healthy subjects, was completed in July 2011.  Results from the first Phase 1 study will be presented at the 2011 American Academy of Pain Management (AAPM) Annual Clinical Meeting on September 21, 2011.

NKTR-181, a novel mu-opioid agonist with an extended pharmacokinetic profile, was created using Nektar's proprietary small molecule polymer conjugate technology.  With slower entry into the CNS when compared to published oxycodone data, NKTR-181 has the potential to greatly reduce the euphoria that underlies opioid abuse liability and dependence.  In addition, NKTR-181 is intended to reduce the other serious CNS-related side effects such as respiratory depression and sedation which are associated with current opioid therapies.  NKTR-181 is a new chemical entity created by small molecule polymer conjugation with unique properties that are inherent to its molecular structure.  As a result, NKTR-181 is also specifically designed to prevent its conversion into a more abusable opioid.

The primary objective of
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
5. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
8. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
9. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
10. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
11. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Humberto C. Antunes,  Galderma  worldwide CEO, will receive a ... of Drugs in Dermatology (JDD) at the upcoming ... is January 17-20, 2014, at the Omni Orlando Resort at ChampionsGate ... The ODAC is a distinguished event that delivers a ...
(Date:1/15/2014)...  In an unprecedented effort to curb the spread of "superbugs" such ... vehicles, an advanced and portable UV germicidal lamp manufactured by MRSA-UV ... In order to prevent EMS paramedics and transport ... West Palm Beach Fire Rescue is the first in ...
(Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... developing its Symphony® CGM System as a non-invasive, wireless ... F. Doman , Executive Chairman and Interim CEO of ... Markets, Tenth Annual Equity Conference. Mr. ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... Chiron Corporation notified the CDC that none of its influenza ... States for the current influenza season. In the wake of ... vaccine supply, medical officials and the general public have grown ... of a looming epidemic. , ,It remains to be seen ...
... PSA test has been widely used as the gold standard ... reversals in recent diagnostic science, a recent study at Stanford ... now put the utility of the procedure in grave doubt. ... States, said Thomas Stamey, MD, professor of urology and lead ...
Cached Medicine Technology:Rapid Flu Tests May Prove Especially Helpful This Season 2Rapid Flu Tests May Prove Especially Helpful This Season 3PSA TestingHow Much is Too Much? 2PSA TestingHow Much is Too Much? 3
(Date:4/18/2014)... 21, 2014) -- A group of scientists from ... the Sanders-Brown Center on Aging has found interesting ... neuropsychological function in Parkinson,s disease (PD). , ... the study, which assessed cognitive function in depressed ... dopamine replacement therapy commonly used to treat motor ...
(Date:4/18/2014)... School of Medicine researchers have been awarded two-year grants ... Nordisk announced this month. Of the 110 initial submissions ... Science Forum Program, only four projects were funded, three ... are Jonathan Powell, M.D., Ph.D.; G. William Wong, Ph.D.; ... a professor of oncology, will use his $500,000 proof ...
(Date:4/18/2014)... A new study in the American Journal of ... searches reveals a recurring pattern that could be leveraged ... from San Diego State University, the Santa Fe Institute, ... Google searches (searches that included the term healthy and ... U.S. from 2005 to 2012. They found that on ...
(Date:4/17/2014)... in non-cancerous prostate tissue may have nearly twice the ... no inflammation, according to results of a new study ... Center. , The link between persistent inflammation and cancer ... cancer those with a Gleason score between 7 ... aggressive and rapidly growing prostate cancers. , "What we,ve ...
(Date:4/17/2014)... study published today in PLOS Pathogens , children ... is common can mount an immune response to infection ... repeated bouts of high fever and illness and partially ... The findings may help researchers develop future interventions that ... parasite. , Each year, approximately 200 million cases of ...
Breaking Medicine News(10 mins):Health News:Treating depression in PD patients: New research 2Health News:New research shows people are thinking about their health early in the week 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2
... Serbia has been reported, much to the concern of the ... been suspected of carrying the deadly H5N1 virus. ... eastern Serbian region have been found to show symptoms of ... to testing laboratory in Britain to confirm the suspicion, said ...
... HIV/AIDS workshop held on Tuesday speakers have raised an ... to prevent it from spreading in the country.// ... a disease” was organised by the provincial AIDS Control ... ,One of the speakers NWFP Health Minister Inayatullah Khan ...
... The stage is set for the final hearing of India's ... hospital charged with negligence in a woman's death eight years ... realise my case can again be postponed by the machinations ... Wednesday, a day ahead of the final hearing at the ...
... About 117,619 frozen embryos are stored in Britain. They are living ... waiting for their lives to begin again. // , ... 1997, but was born in April 2000. Her gestation period lasted ... Lois had been an eight-celled embryo and spent about 30 months ...
... launched the world's largest medical experiment at Altrincham, Cheshire. // ... to the first set of participants. The main aim of ... of cancer, heart disease, diabetes, dementia, joint disease and many ... reveal the truth of why some people would die before ...
... by a team of researchers from Warwick Medical School found ... neglect. // ,The study included 120,000 children born ... who had a low birth weight and were born premature ... ,Premature babies include those that were born before 34 ...
Cached Medicine News:Health News:Stage Set For Final Hearing On India’s Biggest Ever Medical Compensation Clai 2Health News:Frozen embryos stored in Britain 2Health News:UK Biobank Set Up To Understand the Links between Genes, Lifestyle Environment and Illness 2
... from Richmond Products includes the four demonstration plates, ... series for a total of 24 plates. Each ... easy and clean page selection. The test also ... a laminated copy of the score sheet. The ...
Ishihara 14 plate color vision testing set. Suitable for screening purposes....
Accepted by leading authorities as a simple and accurate method for discovering congenital color blindness of two type total color blindness and red/green blindness. This book is used for children an...
... BD Edgeahead Stiletto / MVR knife. 1.1 ... insertion of 1.1 mm (19G) Cannula (5/bx, 1 ... knives are consistently sharp and precise. Sure grip ... edge. Tapered tip creates a fluid tight incision ...
Medicine Products: